NATCOPHARM.NS Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: February 17, 2026
Report Source: 2026 3rd Quarter Report
Natco Pharma Ltd. Stock Analysis NATCOPHARM.NS
NATCO Pharma Ltd. engages in the business of pharmaceuticals with research, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. The company develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. Its segments include Pharmaceuticals and Agro chemicals. The Pharmaceuticals segment is engaged in the manufacturing and selling of bulk drugs, finished dosage formulations. The Agro Chemicals segment focuses on the manufacturing and selling of agro chemicals. The company is also engaged in developing, manufacturing and marketing finished dosage formulations (FDF), active pharmaceutical ingredients (APIs) and intermediates. Its product portfolio consists of two categories of agrochemicals - pesticides and bioproducts. The key focus area is to fill the gaps in the portfolio through crop phenology analysis. The company has manufacturing facilities in India which cater to both domestic and international markets.
Read More Natco Pharma Ltd (NATCOPHARM.NS) Chart
Key Statistics of Natco Pharma Ltd (NATCOPHARM.NS)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
₹1,206.80Volume
573.03KP/E Ratio (TTM)
11.4452 Week Range
Market Cap
199.46BAvg. Volume
698.54KDividend Yield
0.42%Financial Metrics & Statements of Natco Pharma Ltd (NATCOPHARM.NS)
FAQ's for Natco Pharma Ltd (NATCOPHARM.NS)
- According to Musaffa’s Shariah screening methodology, Natco Pharma Ltd (NATCOPHARM.NS) is currently classified as HALAL as of February 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.